TriangleNCT00408005 · OUTCOME
Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- percent probability
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- 4 years from randomization at the end of induction
What was measured
Disease-free survival defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, remission death) or date of last contact for those who are event-free.
Analysis population: Includes only T-cell Acute Lymphoblastic Leukemia (T-ALL) patients randomized to Capizzi Methotrexate (CMTX) versus High-Dose Methotrexate (HDMTX). CNS3 patients non-randomly assigned to HDMTX (Arms III and IV) and Induction failures non-randomly assigned to Arm IV were excluded. T-LLY patients are excluded.
Groups in this outcome
ARM I (Combination Chemotherapy)
No Nelarabine, Capizzi Methotrexate
ARM II (Combination Chemotherapy)
Nelarabine, Capizzi Methotrexate
ARM III (Combination Chemotherapy)
No Nelarabine, High-Dose Methotrexate
ARM IV (Combination Chemotherapy)
Nelarabine, High-Dose Methotrexate
| Group | Source count |
|---|---|
| ARM I (Combination Chemotherapy) | 372 |
| ARM II (Combination Chemotherapy) | 147 |
| ARM III (Combination Chemotherapy) | 367 |
| ARM IV (Combination Chemotherapy) | 145 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| ARM I (Combination Chemotherapy) | 91.76 | Not reported | 88.8 | 94.8 | Not reported |
| ARM II (Combination Chemotherapy) | 90.53 | Not reported | 85.0 | 96.0 | Not reported |
| ARM III (Combination Chemotherapy) | 86.06 | Not reported | 82.2 | 89.9 | Not reported |
| ARM IV (Combination Chemotherapy) | 84.89 | Not reported | 78.0 | 91.8 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 88.8
- upper Limit
- 94.8
- value
- 91.76
- group Id
- OG001
- lower Limit
- 85.0
- upper Limit
- 96.0
- value
- 90.53
- group Id
- OG002
- lower Limit
- 82.2
- upper Limit
- 89.9
- value
- 86.06
- group Id
- OG003
- lower Limit
- 78.0
- upper Limit
- 91.8
- value
- 84.89
- denoms
- counts
- group Id
- OG000
- value
- 372
- group Id
- OG001
- value
- 147
- group Id
- OG002
- value
- 367
- group Id
- OG003
- value
- 145
- units
- Participants
- description
- Disease-free survival defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, remission death) or date of last contact for those who are event-free.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- No Nelarabine, Capizzi Methotrexate
- id
- OG000
- title
- ARM I (Combination Chemotherapy)
- description
- Nelarabine, Capizzi Methotrexate
- id
- OG001
- title
- ARM II (Combination Chemotherapy)
- description
- No Nelarabine, High-Dose Methotrexate
- id
- OG002
- title
- ARM III (Combination Chemotherapy)
- description
- Nelarabine, High-Dose Methotrexate
- id
- OG003
- title
- ARM IV (Combination Chemotherapy)
- param Type
- NUMBER
- population Description
- Includes only T-cell Acute Lymphoblastic Leukemia (T-ALL) patients randomized to Capizzi Methotrexate (CMTX) versus High-Dose Methotrexate (HDMTX). CNS3 patients non-randomly assigned to HDMTX (Arms III and IV) and Induction failures non-randomly assigned to Arm IV were excluded. T-LLY patients are excluded.
- reporting Status
- POSTED
- time Frame
- 4 years from randomization at the end of induction
- title
- Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)
- type
- PRIMARY
- unit Of Measure
- percent probability
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice